- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07799610
Senior Center Medication Safety and Empowerment Curriculum
27. august 2026 opdateret af: Robert Wahler, State University of New York at Buffalo
Team Alice Senior Center Medication Safety and Empowerment Curriculum
Team Alice's Medication Safety and Empowerment Curriculum (MedSEC) helps older adults and caregivers learn how to safely manage medications.
Many seniors take multiple medications, which can lead to harmful side effects or unnecessary treatments.
This program, developed at the University at Buffalo, will be offered at senior centers in Western New York.
It includes two interactive sessions that teach participants how to recognize medication risks and talk with their doctors about safer options.
The curriculum uses videos, group discussions, and hands-on tools to build confidence and knowledge.
It follows the "4Ms" of Age-Friendly Health Systems: What Matters, Medication, Mentation, and Mobility.
A "Train-the-Trainer" model will help senior center staff continue the program long-term.
The goal is to reduce medication harm, improve communication with healthcare providers, and support healthy aging in the community.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
125
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
New York
-
Buffalo, New York, Forenede Stater, 142148033
- Rekruttering
- University at Buffalo
-
Kontakt:
- Robert G Wahler, Doctor of Pharmacy
- Telefonnummer: 7166454777
- E-mail: rgwahler@buffalo.edu
-
Ledende efterforsker:
- Robert G Wahler, Doctor of Pharmacy
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- 55 years of age and above
- taking prescription medications
Carepartner Inclusion Criteria:
- currently an informal or formal care partner for an eligible patient (regardless of whether they live with or near the patient)
- aged 18 years of age and above
Exclusion Criteria:
- Patients with cognitive impairment that prevents their self-management of medications.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Patient Activation Measure (PAM)
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Patient Activation Measure (PAM).
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
|
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Revised Patient Attitudes Towards Deprescribing (rPATD) questionnaires.
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Revised Patient Attitudes Towards Deprescirbing (rPATD) questionnaires.
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in participant understanding of medication safety risks at 6 Months.
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
85% of participants will demonstrate an understanding of medication safety risks through pre- and post-program patient/caregiver questionnaires, including the Patient Activation Measure (PAM) and Revised Patient Attitudes to Deprescribing (rPATD).
Additional questions pertaining to knowledge retention and actionability will be asked at 6 months.
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
|
Participants will demonstrate knowledge of the 4Ms (Age-Friendly Health System) framework through pre/post/6 month follow up questionnaires.
Tidsramme: Change from baseline, post-program assessment (immediately after program completion), and 6 months after program completion.
|
By the end of the program, 80% of participants will demonstate knowledge of the 4Ms framework, measured by four questions related to the 4Ms and the Age-Friendly Health System taken prior to the program, immediately post-program, and 6 months after program completion.
|
Change from baseline, post-program assessment (immediately after program completion), and 6 months after program completion.
|
|
Change in patient engagement as measured by the Patient Activation Measure (PAM) from baseline to 6 months post program.
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
6 months post-program, 65% of participants will show improved patient engagement, as measured by the Patient Activation Measure (PAM) questionnaire.
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
|
Change from baseline in the mean of medications after 6 months follow-up
Tidsramme: Change from baseline and 6 months after program completion.
|
Within 6 months of completing program, 50% of participants with polypharmacy will have reduced medication usage by 10%.
(mean # of medications.)
|
Change from baseline and 6 months after program completion.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Post-Survey to Measure Program Impact and Participant Satisfaction
Tidsramme: Post curriculum session 2 (immediately after educational session 2, Day 7)
|
A post-survey questionnaire (immediately after program completion) will be used to assess the program's educational value and determine its effectiveness in increasing medication safety knowledge, empowerment, and patient self-advocacy, as well as participant satisfaction.
|
Post curriculum session 2 (immediately after educational session 2, Day 7)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. februar 2026
Primær færdiggørelse (Anslået)
1. februar 2027
Studieafslutning (Anslået)
31. marts 2027
Datoer for studieregistrering
Først indsendt
21. november 2025
Først indsendt, der opfyldte QC-kriterier
27. august 2026
Først opslået (Faktiske)
2. september 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
2. september 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
27. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00009882
- G-202509-02155 (Andet bevillings-/finansieringsnummer: Health Foundation for Western & Central New York)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .